Clinical trial
Study of Recombinant Interleukin 21 in Combination With Rituxan for…
NCT00347971 · ZymoGenetics, Industry · Completed
Key facts
| NCT number | NCT00347971 |
|---|---|
| Title | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma |
| Official title | Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered in Combination With Rituxan (Rituximab) in Subjects With B-Cell Non Hodgkin's Lymphoma |
| Lead sponsor | ZymoGenetics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | recombinant human interleukin 21 and rituximab |
| Enrollment | 23 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jul 4, 2006 |
| Last update posted | Sep 5, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: